Generex Biotechnology steigt und steigt ( Seite 210)

Generex to Pursue Regulatory Path for Application of Generex Oral-lyn(tm) for Veterinary Market

WORCESTER, Mass., Mar 26, 2009 (GlobeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that as a result of increased demand, the company plans to pursue the regulatory path for the submission of Generex Oral-lyn(tm) with the veterinary arms of global health agencies for therapeutic use in cats and dogs with diabetes.

Diabetes Mellitus is a relatively common metabolic disease seen in middle-aged cats and dogs. Dogs with diabetes typically suffer from Type 1, while affected cats typically have Type 2. In addition to insulin, the veterinary management of diabetes requires regular glucose testing, pet owner education and the common application of diet and exercise.

"Generex Oral-lyn(tm) is a pain-free insulin delivery method for people to better manage their diabetes," said Anna Gluskin, president and chief executive officer of Generex. "But we realize that for many people, their pets are members of the family, so with one in every 500 cats and dogs developing diabetes in its lifetime, we want to offer Generex Oral-lyn(tm) to care for them as well."

According to Pet Health: Products/Services Report, the pet health industry in the United States alone is a $21 billion market and is expected to grow by 7.1 percent annually through 2011.

Generex's anticipated timeline for submission to the appropriate health agencies for this indication is some time in the second half of calendar year 2009.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral sta

Antwort auf Beitrag Nr.: 36.858.384 von Netflirter am 26.03.09 20:06:46Hallo netflirter,

und dann hat es booom gemacht. Zumindest ein kleines. Aber so kanns von mir aus weitergehen.

:-)

vg

keep

Antwort auf Beitrag Nr.: 36.858.736 von keep-racing am 26.03.09 20:43:14Hallo keep
jop so ist es wer weiß viehleicht ergehts unseren Baby ja genauso wie Cell heute
lg Netflirter

Antwort auf Beitrag Nr.: 36.858.794 von Netflirter am 26.03.09 20:50:49Cell??? Hilf mir ein bisserl weiter, manchmal bin ich ein bisserl deppert. :-)

kein ding man kann nich alles wissen Cell Therapeutics sind heute um 200% abgegangen

Antwort auf Beitrag Nr.: 36.858.926 von Netflirter am 26.03.09 21:03:29thx.

Ja das wär schon, ich hoffe auch das kommt noch...

vg

keep

bitte
so heute is Hauptversammlung viehleicht gibt das den nächsten Schub

Antwort auf Beitrag Nr.: 36.863.794 von Netflirter am 27.03.09 12:41:40schaun mer mal.